Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JASON M HAFFIZULLA

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1033281191
CMS profile
228449
Location
TAMARAC, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$2,439.93

149 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,393.37 146
Education $46.56 3

By paying entity

PY2019 · entire year · sorted by reported total

Page 3 of 3; records 101–149 of 149 matching records. This page contains 49 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JASON M HAFFIZULLA

NPI 1033281191 · CMS profile ID 228449

Allopathic & Osteopathic Physicians / Internal Medicine

TAMARAC, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–149 of 149 matching records. This page contains 49 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1033281191?year=2019&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JASON M HAFFIZULLA, NPI 1033281191, CMS profile ID 228449. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–149 of 149 matching records. This page contains 49 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1033281191?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). JASON M HAFFIZULLA, NPI 1033281191, CMS profile ID 228449. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–149 of 149 matching records. This page contains 49 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1033281191?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
JASON M HAFFIZULLA, NPI 1033281191, CMS profile ID 228449, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–149 of 149 matching records. This page contains 49 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1033281191?year=2019&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

149 matching records · $2,439.93 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 149 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–149 of 149.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novartis Pharmaceuticals Corporation $18.6005/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659617867 CMS
Novo Nordisk Inc $4.3605/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682723843 CMS
Radius Health, Inc. $20.0005/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 683931123 CMS
AbbVie, Inc. $23.2304/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648022003 CMS
PFIZER INC. $2.6704/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671982159 CMS
AstraZeneca Pharmaceuticals LP $8.7604/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685994871 CMS
Novartis Pharmaceuticals Corporation $12.0404/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659617865 CMS
PFIZER INC. $15.5804/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671991527 CMS
Janssen Pharmaceuticals, Inc $15.5304/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658680751 CMS
Novo Nordisk Inc $14.7304/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 669552315 CMS
Cumberland Pharmaceuticals, Inc. $18.9104/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699729939 CMS
GlaxoSmithKline, LLC. $17.5004/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671387783 CMS
Mylan Specialty L.P. $20.0604/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694815947 CMS
Lilly USA, LLC $13.6304/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657893959 CMS
PFIZER INC. $16.0504/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671981731 CMS
Novo Nordisk Inc $19.6003/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 669466719 CMS
Zyla Life Sciences $14.2103/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704861281 CMS
SANOFI-AVENTIS U.S. LLC $21.4703/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693941821 CMS
AstraZeneca Pharmaceuticals LP $17.6603/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685904365 CMS
Mallinckrodt Enterprises LLC $16.7403/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704746419 CMS
Novo Nordisk Inc $16.8003/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 669466721 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $25.9503/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700177749 CMS
AstraZeneca Pharmaceuticals LP $18.8203/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685954113 CMS
Merck Sharp & Dohme Corporation $18.6303/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695339559 CMS
Zyla Life Sciences $13.7303/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704829325 CMS
Janssen Pharmaceuticals, Inc $16.2603/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658680747 CMS
PFIZER INC. $34.9503/04/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672182099 CMS
Sunovion Pharmaceuticals Inc. $25.0003/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688200627 CMS
Amgen Inc. $4.4603/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663334081 CMS
Mylan Specialty L.P. $23.4903/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694776613 CMS
Amgen Inc. $17.1502/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662469301 CMS
Sunovion Pharmaceuticals Inc. $11.8902/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688200625 CMS
Novo Nordisk Inc $18.0902/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 668753601 CMS
Horizon Therapeutics plc $12.7402/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 691390827 CMS
Lilly USA, LLC $11.7702/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657887067 CMS
Amgen Inc. $19.8402/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662469293 CMS
Novo Nordisk Inc $13.9002/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 668753591 CMS
Novo Nordisk Inc $12.7402/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 668753587 CMS
AstraZeneca Pharmaceuticals LP $18.4202/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685320299 CMS
Merck Sharp & Dohme Corporation $8.1101/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695246147 CMS
Merck Sharp & Dohme Corporation $16.9401/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695257231 CMS
Amgen Inc. $24.6101/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662469315 CMS
Amgen Inc. $5.2301/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662469289 CMS
Novo Nordisk Inc $16.8301/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 668753599 CMS
Novo Nordisk Inc $22.4501/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 668753603 CMS
Regeneron Healthcare Solutions, Inc. $21.3601/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673389533 CMS
GlaxoSmithKline, LLC. $17.6501/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670359123 CMS
Genentech USA, Inc. $16.9201/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681265579 CMS
AstraZeneca Pharmaceuticals LP $16.0501/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685285001 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,439.93 149
PY2020 $2,614.96 164
PY2021 $2,927.15 196
PY2022 $2,866.08 166
PY2023 $2,500.63 131
PY2024 $2,909.41 155
PY2025 $2,206.85 114

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $3,049,251.11 293
PY2024 Recipient $13,760.00 2
PY2024 Principal investigator $1,644,692.43 583
PY2023 Recipient $88,901.84 7
PY2023 Principal investigator $984,196.67 889
PY2022 Recipient $447.00 1
PY2022 Principal investigator $680,075.51 140
PY2021 Principal investigator $565,485.44 41
PY2020 Principal investigator $60,967.71 24
PY2019 Principal investigator $110,486.75 23

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

293 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $12,330.00 12/31/2025 Non-covered Recipient Entity
Precision Clinical Research
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228726084
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267450
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267452
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267454
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267456
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267460
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267462
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267464
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267466
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267468
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267470
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267472
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267474
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267476
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267478
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267480
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267482
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267484
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267486
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267488
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267490
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267492
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267494
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267496
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267498
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267500
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267502
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267504
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267506
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267508
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267510
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267514
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267516
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267518
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267520
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267522
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267524
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267526
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267528
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267530
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267532
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267534
Principal investigator 1 Seqirus USA Inc $864.00 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267536
Principal investigator 1 Seqirus USA Inc $864.00 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267538
Principal investigator 1 Seqirus USA Inc $864.00 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267540
Principal investigator 1 Seqirus USA Inc $864.00 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267542
Principal investigator 1 Seqirus USA Inc $864.00 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267544
Principal investigator 1 Seqirus USA Inc $864.00 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267546
Principal investigator 1 Seqirus USA Inc $864.00 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267548
Principal investigator 1 Seqirus USA Inc $864.00 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267550
Principal investigator 1 Seqirus USA Inc $864.00 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267552
Principal investigator 1 Seqirus USA Inc $864.00 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267554
Principal investigator 1 Seqirus USA Inc $864.00 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267556
Principal investigator 1 Seqirus USA Inc $864.00 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267558
Principal investigator 1 Seqirus USA Inc $864.00 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267560
Principal investigator 1 Seqirus USA Inc $864.00 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267562
Principal investigator 1 Seqirus USA Inc $864.00 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267564
Principal investigator 1 Seqirus USA Inc $864.00 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267566
Principal investigator 1 Seqirus USA Inc $864.00 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267568
Principal investigator 1 Seqirus USA Inc $864.00 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267570
Principal investigator 1 Seqirus USA Inc $864.00 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267572
Principal investigator 1 Seqirus USA Inc $864.00 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267574
Principal investigator 1 Seqirus USA Inc $864.00 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267576
Principal investigator 1 Seqirus USA Inc $864.00 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267578
Principal investigator 1 Seqirus USA Inc $864.00 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267580
Principal investigator 1 Seqirus USA Inc $864.00 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267582
Principal investigator 1 Seqirus USA Inc $864.00 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267584
Principal investigator 1 Seqirus USA Inc $864.00 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267586
Principal investigator 1 Seqirus USA Inc $864.00 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267588
Principal investigator 1 Seqirus USA Inc $864.00 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267590
Principal investigator 1 Seqirus USA Inc $864.00 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267592
Principal investigator 1 Seqirus USA Inc $864.00 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267594
Principal investigator 1 Seqirus USA Inc $630.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267596
Principal investigator 1 Seqirus USA Inc $630.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267598
Principal investigator 1 Seqirus USA Inc $630.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267600
Principal investigator 1 Seqirus USA Inc $630.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267602
Principal investigator 1 Seqirus USA Inc $630.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267604
Principal investigator 1 Seqirus USA Inc $313.20 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267606
Principal investigator 1 Seqirus USA Inc $313.20 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267608
Principal investigator 1 Seqirus USA Inc $313.20 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267610
Principal investigator 1 Seqirus USA Inc $313.20 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267612
Principal investigator 1 Seqirus USA Inc $313.20 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267614
Principal investigator 1 Seqirus USA Inc $313.20 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267616
Principal investigator 1 Seqirus USA Inc $313.20 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267618
Principal investigator 1 Seqirus USA Inc $313.20 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267620
Principal investigator 1 Seqirus USA Inc $313.20 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267622
Principal investigator 1 Seqirus USA Inc $313.20 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267624
Principal investigator 1 Seqirus USA Inc $313.20 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267626
Principal investigator 1 Seqirus USA Inc $313.20 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267680
Principal investigator 1 Seqirus USA Inc $630.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267682
Principal investigator 1 Seqirus USA Inc $864.00 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267684
Principal investigator 1 Seqirus USA Inc $891.00 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267686
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267694
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267698
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267738
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267740
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267742
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267744
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267746
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267748
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267750
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267752
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267754
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267756
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267758
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267760
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267762
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267764
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267766
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267768
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267770
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267772
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267774
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267776
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267778
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267780
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267782
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267784
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267786
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267788
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267790
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267792
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267794
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267796
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267800
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267802
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267804
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267806
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267808
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267810
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267812
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267814
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267816
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267818
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267820
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267822
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267824
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267826
Principal investigator 1 Seqirus USA Inc $2,547.45 12/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267828
Principal investigator 1 PFIZER INC. $1,515.00 12/16/2025 Non-covered Recipient Entity
Precision Clinical Research
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228728441
Principal investigator 1 PFIZER INC. $2,106.00 12/16/2025 Non-covered Recipient Entity
Precision Clinical Research
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228728443
Principal investigator 1 PFIZER INC. $1,515.00 12/16/2025 Non-covered Recipient Entity
Precision Clinical Research
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228728521
Principal investigator 1 PFIZER INC. $2,106.00 12/16/2025 Non-covered Recipient Entity
Precision Clinical Research
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228729462
Principal investigator 1 Seqirus USA Inc $1,880.00 12/08/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267688
Principal investigator 1 Seqirus USA Inc $2,547.45 11/27/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267692
Principal investigator 1 Seqirus USA Inc $2,547.45 11/27/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267700
Principal investigator 1 Seqirus USA Inc $2,547.45 11/27/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267702
Principal investigator 1 Seqirus USA Inc $2,547.45 11/27/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267704
Principal investigator 1 Seqirus USA Inc $2,547.45 11/27/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267706
Principal investigator 1 Seqirus USA Inc $2,547.45 11/27/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267708
Principal investigator 1 Seqirus USA Inc $2,547.45 11/27/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267710
Principal investigator 1 Seqirus USA Inc $2,547.45 11/27/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267712
Principal investigator 1 Seqirus USA Inc $2,547.45 11/27/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267714
Principal investigator 1 Seqirus USA Inc $2,547.45 11/27/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267716
Principal investigator 1 Seqirus USA Inc $2,547.45 11/27/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267718
Principal investigator 1 Seqirus USA Inc $2,547.45 11/27/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267720
Principal investigator 1 Seqirus USA Inc $2,547.45 11/27/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267722
Principal investigator 1 Seqirus USA Inc $2,547.45 11/27/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267724
Principal investigator 1 Seqirus USA Inc $2,547.45 11/27/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267726
Principal investigator 1 Seqirus USA Inc $2,547.45 11/27/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267728
Principal investigator 1 Seqirus USA Inc $2,547.45 11/27/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267730
Principal investigator 1 Seqirus USA Inc $2,547.45 11/27/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267732
Principal investigator 1 Seqirus USA Inc $2,547.45 11/27/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267734
Principal investigator 1 Seqirus USA Inc $2,547.45 11/27/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267736
Principal investigator 1 Seqirus USA Inc $7,500.00 11/25/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267696
Principal investigator 1 ModernaTX, Inc. $273.20 11/19/2025 Non-covered Recipient Entity
Precision Clinical Research, LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252993998
Principal investigator 1 ModernaTX, Inc. $273.20 11/17/2025 Non-covered Recipient Entity
Precision Clinical Research, LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252994028
Principal investigator 1 Seqirus USA Inc $5,812.64 11/12/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1250809608
Principal investigator 1 Seqirus USA Inc $1,620.81 11/12/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1250809613
Principal investigator 1 ModernaTX, Inc. $1,566.00 10/30/2025 Non-covered Recipient Entity
Precision Clinical Research, LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252994030
Principal investigator 1 Seqirus USA Inc $5,128.80 10/30/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1250809596
Principal investigator 1 Seqirus USA Inc $1,409.40 10/30/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1250809602
Principal investigator 1 ModernaTX, Inc. $103,858.93 10/29/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252993978
Principal investigator 1 ModernaTX, Inc. $11,089.54 10/29/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252993980
Principal investigator 1 ModernaTX, Inc. $116.32 10/29/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252993982
Principal investigator 1 ModernaTX, Inc. $10,768.91 10/29/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252993984
Principal investigator 1 ModernaTX, Inc. $913.62 10/29/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252994008
Principal investigator 1 ModernaTX, Inc. $42,902.44 10/29/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252994010
Principal investigator 1 ModernaTX, Inc. $11,501.00 10/29/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252994012
Principal investigator 1 ModernaTX, Inc. $2,381.58 10/29/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252994034
Principal investigator 1 ModernaTX, Inc. $10,590.32 10/29/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252994040
Principal investigator 1 ModernaTX, Inc. $8,901.10 10/29/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252994068
Principal investigator 1 ModernaTX, Inc. $10,600.25 10/29/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252994070
Principal investigator 1 ModernaTX, Inc. $10,500.16 10/29/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252994072
Principal investigator 1 ModernaTX, Inc. $277.05 10/29/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252994076
Principal investigator 1 ModernaTX, Inc. $13,272.00 10/29/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252994078
Principal investigator 1 ModernaTX, Inc. $57,798.44 10/27/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252994002
Principal investigator 1 ModernaTX, Inc. $13,938.47 10/27/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252994024
Principal investigator 1 ModernaTX, Inc. $57,810.60 10/27/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252994042
Principal investigator 1 ModernaTX, Inc. $3,077.57 10/27/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252994058
Principal investigator 1 ModernaTX, Inc. $106,458.74 10/27/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252994062
Principal investigator 1 ModernaTX, Inc. $2,442.96 10/27/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252994082
Principal investigator 1 ModernaTX, Inc. $2,362.70 10/27/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252994084
Principal investigator 1 ModernaTX, Inc. $500.00 10/15/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252994006
Principal investigator 1 ModernaTX, Inc. $2,000.00 10/15/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252994032
Principal investigator 1 ModernaTX, Inc. $1,800.00 10/15/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252994038
Principal investigator 1 Seqirus USA Inc $110.98 09/09/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267676
Principal investigator 1 Seqirus USA Inc $111.30 09/09/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267678
Principal investigator 1 Seqirus USA Inc $1,893.60 09/09/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185267690
Principal investigator 1 ModernaTX, Inc. $7,505.33 07/28/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252994016
Principal investigator 1 ModernaTX, Inc. $4,840.71 07/28/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252994060
Principal investigator 1 ModernaTX, Inc. $22,803.07 07/28/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252994066
Principal investigator 1 Seqirus USA Inc $1,200.00 07/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185267672
Principal investigator 1 Seqirus USA Inc $1,500.00 07/18/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185267674
Principal investigator 1 ModernaTX, Inc. $53,157.16 06/27/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252993994
Principal investigator 1 ModernaTX, Inc. $39,825.08 06/27/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252993996
Principal investigator 1 ModernaTX, Inc. $8,143.20 06/27/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252994050
Principal investigator 1 ModernaTX, Inc. $3,023.28 06/27/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252994090
Principal investigator 1 ModernaTX, Inc. $203,716.10 06/27/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252994094
Principal investigator 1 ModernaTX, Inc. $5,836.32 05/12/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252994074
Principal investigator 1 ModernaTX, Inc. $238,950.48 04/28/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252993990
Principal investigator 1 ModernaTX, Inc. $3,155.49 04/28/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252994000
Principal investigator 1 ModernaTX, Inc. $32,860.62 04/28/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252994020
Principal investigator 1 ModernaTX, Inc. $43,085.98 04/28/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252994048
Principal investigator 1 ModernaTX, Inc. $60,608.59 04/28/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252994052
Principal investigator 1 ModernaTX, Inc. $67,547.97 04/28/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252994056
Principal investigator 1 ModernaTX, Inc. $5,700.24 04/28/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252994080
Principal investigator 1 ModernaTX, Inc. $2,362.70 04/28/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252994088
Principal investigator 1 Seqirus USA Inc $504.00 04/09/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185267628
Principal investigator 1 Seqirus USA Inc $1,065.00 04/09/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185267630
Principal investigator 1 Seqirus USA Inc $1,065.00 04/09/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185267632
Principal investigator 1 Seqirus USA Inc $1,065.00 04/09/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185267634
Principal investigator 1 Seqirus USA Inc $1,065.00 04/09/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185267636
Principal investigator 1 Seqirus USA Inc $1,065.00 04/09/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185267638
Principal investigator 1 Seqirus USA Inc $1,065.00 04/09/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185267640
Principal investigator 1 Seqirus USA Inc $504.00 04/09/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185267642
Principal investigator 1 Seqirus USA Inc $1,065.00 04/09/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185267644
Principal investigator 1 Seqirus USA Inc $504.00 04/09/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185267646
Principal investigator 1 Seqirus USA Inc $1,065.00 04/09/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185267648
Principal investigator 1 Seqirus USA Inc $751.00 04/09/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185267650
Principal investigator 1 Seqirus USA Inc $751.00 04/09/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185267652
Principal investigator 1 Seqirus USA Inc $1,065.00 04/09/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185267654
Principal investigator 1 Seqirus USA Inc $504.00 04/09/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185267656
Principal investigator 1 Seqirus USA Inc $1,065.00 04/09/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185267658
Principal investigator 1 Seqirus USA Inc $504.00 04/09/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185267660
Principal investigator 1 Seqirus USA Inc $1,065.00 04/09/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185267662
Principal investigator 1 Seqirus USA Inc $751.00 04/09/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185267664
Principal investigator 1 Seqirus USA Inc $1,065.00 04/09/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185267666
Principal investigator 1 Seqirus USA Inc $504.00 04/09/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185267668
Principal investigator 1 Seqirus USA Inc $1,065.00 04/09/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185267670
Principal investigator 1 Seqirus USA Inc $1,065.00 04/09/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185267854
Principal investigator 1 Seqirus USA Inc $751.00 04/09/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185267856
Principal investigator 1 Seqirus USA Inc $504.00 04/09/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185267858
Principal investigator 1 Seqirus USA Inc $1,065.00 04/09/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185267948
Principal investigator 1 Seqirus USA Inc $504.00 04/09/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185267950
Principal investigator 1 Seqirus USA Inc $1,065.00 04/09/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185267952
Principal investigator 1 Seqirus USA Inc $504.00 04/09/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185267954
Principal investigator 1 Seqirus USA Inc $1,065.00 04/09/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185267956
Principal investigator 1 Seqirus USA Inc $1,065.00 04/09/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185267958
Principal investigator 1 Seqirus USA Inc $1,065.00 04/09/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185267960
Principal investigator 1 Seqirus USA Inc $1,065.00 04/09/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185267962
Principal investigator 1 Seqirus USA Inc $1,065.00 04/09/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185267964
Principal investigator 1 Seqirus USA Inc $1,065.00 04/09/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185267966
Principal investigator 1 Seqirus USA Inc $504.00 04/09/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185267968
Principal investigator 1 Seqirus USA Inc $1,065.00 04/09/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185267970
Principal investigator 1 Seqirus USA Inc $504.00 04/09/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185267972
Principal investigator 1 Seqirus USA Inc $504.00 04/09/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185267974
Principal investigator 1 Seqirus USA Inc $504.00 04/09/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185267976
Principal investigator 1 Seqirus USA Inc $504.00 04/09/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185267978
Principal investigator 1 Seqirus USA Inc $504.00 04/09/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185267980
Principal investigator 1 Seqirus USA Inc $504.00 04/09/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185267982
Principal investigator 1 Seqirus USA Inc $504.00 04/09/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185267984
Principal investigator 1 Seqirus USA Inc $1,065.00 04/09/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185267986
Principal investigator 1 Seqirus USA Inc $1,065.00 04/09/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185267988
Principal investigator 1 Seqirus USA Inc $1,065.00 04/09/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185267990
Principal investigator 1 ModernaTX, Inc. $2,465.00 03/24/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252994004
Principal investigator 1 ModernaTX, Inc. $5,700.24 01/30/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252993986
Principal investigator 1 ModernaTX, Inc. $43,837.56 01/30/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252993988
Principal investigator 1 ModernaTX, Inc. $52,917.93 01/30/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252993992
Principal investigator 1 ModernaTX, Inc. $133,927.89 01/30/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252994022
Principal investigator 1 ModernaTX, Inc. $34,338.22 01/30/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252994046
Principal investigator 1 ModernaTX, Inc. $68,518.30 01/30/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252994086
Principal investigator 1 ModernaTX, Inc. $593,971.01 01/30/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252994092
Principal investigator 1 ModernaTX, Inc. $244,864.62 01/30/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252994096
Principal investigator 1 ModernaTX, Inc. $27,115.00 01/29/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 No dispute reported 06/30/2026 1252994036
Principal investigator 1 ModernaTX, Inc. $48,496.67 01/27/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252994014
Principal investigator 1 ModernaTX, Inc. $34,980.66 01/27/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252994018
Principal investigator 1 ModernaTX, Inc. $3,518.19 01/27/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252994026
Principal investigator 1 ModernaTX, Inc. $2,442.96 01/27/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252994044
Principal investigator 1 ModernaTX, Inc. $11,766.37 01/27/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252994054
Principal investigator 1 ModernaTX, Inc. $36,930.84 01/27/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252994064
Principal investigator 1 Seqirus USA Inc $1,065.00 01/22/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185267830
Principal investigator 1 Seqirus USA Inc $504.00 01/22/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185267832
Principal investigator 1 Seqirus USA Inc $504.00 01/22/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185267834
Principal investigator 1 Seqirus USA Inc $504.00 01/22/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185267836
Principal investigator 1 Seqirus USA Inc $504.00 01/22/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185267838
Principal investigator 1 Seqirus USA Inc $504.00 01/22/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185267842
Principal investigator 1 Seqirus USA Inc $504.00 01/22/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185267844
Principal investigator 1 Seqirus USA Inc $504.00 01/22/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185267846
Principal investigator 1 Seqirus USA Inc $504.00 01/22/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185267848
Principal investigator 1 Seqirus USA Inc $1,065.00 01/22/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185267850
Principal investigator 1 Seqirus USA Inc $1,065.00 01/22/2025 Non-covered Recipient Entity
Precision Clinical Research Inc
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older No dispute reported 06/30/2026 1185267852
Principal investigator 1 AstraZeneca Pharmaceuticals LP $7,793.00 01/03/2025 Non-covered Recipient Entity
PRECISION CLINICAL RESEARCH, INC
a phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like particle VLP vaccine in adults 60 years of age and older No dispute reported 06/30/2026 1185554512